Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

N. Kutsch, R. Busch, J. Bahlo, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, CM. Wendtner, A. Maria Fink, K. Fischer, M. Hallek, B. Eichhorst,

. 2017 ; 58 (2) : 399-407. [pub] 20160629

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011138

The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011138
003      
CZ-PrNML
005      
20180416095026.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/10428194.2016.1190966 $2 doi
035    __
$a (PubMed)27357445
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kutsch, Nadine $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
245    10
$a FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia / $c N. Kutsch, R. Busch, J. Bahlo, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, CM. Wendtner, A. Maria Fink, K. Fischer, M. Hallek, B. Eichhorst,
520    9_
$a The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a adherence k farmakoterapii $7 D055118
650    _2
$a lidé středního věku $7 D008875
650    12
$a kvalita života $7 D011788
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a sexuální faktory $7 D012737
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vidarabin $x aplikace a dávkování $x analogy a deriváty $7 D014740
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Busch, Raymonde $u b Institute of Medical Statistics and Epidemiology , Technical University , Munich , Germany.
700    1_
$a Bahlo, Jasmin $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
700    1_
$a Mayer, Jiri $u c Department of Internal Medicine, Hematology and Oncology , University Hospital Brno , Brno , Czech Republic.
700    1_
$a Hensel, Manfred $u d Internal Medicine V , University of Heidelberg , Heidelberg , Germany.
700    1_
$a Hopfinger, Georg $u e Department of Internal Medicine I, Vienna General Hospital, Medical University of Vienna , Vienna , Austria.
700    1_
$a Hess, Georg $u f Department of Hematology and Oncology , Johannes Gutenberg-Universitat , Mainz , Germany.
700    1_
$a von Grünhagen, Ulrich $u g Praxis fur Hamatologie und Onkologie , Cottbus , Germany.
700    1_
$a Wendtner, Clemens-Martin $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany. h Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine , Klinikum Schwabing , Munich , Germany.
700    1_
$a Maria Fink, Anna $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
700    1_
$a Fischer, Kirsten $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
700    1_
$a Hallek, Michael $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
700    1_
$a Eichhorst, Barbara $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
773    0_
$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 58, č. 2 (2017), s. 399-407
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27357445 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180416095123 $b ABA008
999    __
$a ok $b bmc $g 1288623 $s 1007950
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 58 $c 2 $d 399-407 $e 20160629 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...